(149) demonstrated that type II endometrial cancer cells with high CLDN3 and CLDN4 expression could be effectively targeted using intraperitoneal administration of Clostridium perfringens enterotoxin (CPE) in murine xenograft models. This evidence concerns the gene CLDN3 and endometrial cancer.